A / A / A

publications

Medicine and Public Health

Providing care to individuals, responding to disasters

What are the challenges, limitations, constraints, paradoxes and potential breakthroughs of humanitarian medicine, which specialises in treating marginalised and deprived populations affected by crises? Deconstructing a number of “healthcare utopias,” the studies contained in this volume review the history of global health innovations to which MSF has contributed. They also explore the current state of knowledge, practices and concerns relating to certain focus areas, such as nutrition, AIDS, water supply, food aid, reconstructive surgery, epidemic response, surveillance and disaster epidemiology.

Goma Jacob Burns Analysis

Too much Never Enough : Social Support at MSF

06/24/2024 Jacob Burns

In this paper, Jacob Burns analyzes MSF's activities in the provision of social support.  In the introduction, he suggests a rough outline of different ‘social’ problems that MSF has turned to between the 1980s and the 2010s. The second part of the paper is a report of a field visit conducted in October – November 2023 to Goma, DRC.

Read more
Southern Chhattisgarh Mobile Clinics Tadeu Andre/MSF Cahier

Access to health products: which priorities and what role for MSF?

05/26/2023 Michaël Neuman Natalie Roberts

On 3rd and 4th February 2022, the CRASH organised a workshop aimed principally at the directors and operational managers of MSF Operational Centre Paris (OCP) to reflect on current debates, and to determine which elements of the discussion would be the most relevant to resolve to support the advancement of MSF OCP’s operational projects. Is access to medicines the same issue today as it was when MSF first became interested in the mid-1990s? Rather than just concentrating on the obstacles to accessing medicines, should the debate be broadened to encompass what are now called ‘health products’ or even further, towards access to care and thus largely structural problems of human resources, financing, or the absence of national health insurance policies?

Read more
Stopping HIV in Ndhiwa Wairimu Gitau/MSF Interview

Controlling an HIV Hotspot. A Realistic Ambition?

11/30/2022 Pierre Mendiharat Elba Rahmouni Léon Salumu Luzinga

This article was published on December 22nd, 2021, in the Journal of Humanitarian Affairs (Issue 3, Volume 3).
Despite a concerted international effort in recent decades that has yielded significant progress in the fight against HIV/AIDS, the disease continues to kill large numbers of people, especially in certain regions like rural Ndhiwa district in Homa Bay County, Kenya. Although there is still no definitive cure or vaccine, UNAIDS has set an ambitious goal of ending the epidemic by 2030, specifically via its 90-90-90 (treatment cascade) strategy – namely that 90 per cent of those with HIV will know their status; 90 per cent of those who know their status will be on antiretroviral therapy and 90 per cent of those on antiretroviral therapy will have an undetectable viral load. These bold assumptions were put to the test in a five-year pilot project launched in June 2014 by Médecins Sans Frontières (MSF) and Kenya’s Ministry of Health in Ndhiwa district, where an initial NHIPS 1 study by Epicentre (MSF’s epidemiology centre) in 2012 revealed some of the world’s highest HIV incidence and prevalence, and a poor “treatment cascade”. Six years later a new Epicentre study, NHIPS 2, showed that the 90-90-90 target had been more than met. What explains this ‘success’? And given the still-high incidence, is it truly a success? What follows is an interview on the political, scientific, and operational challenges of the Ndhiwa project with MSF Deputy Director of Operations Pierre Mendiharat and physician Léon Salumu, Head of MSF France Kenya programs, conducted by Elba Rahmouni.

Read more
image ce que nous dit le sida Njiiri Karago/MSF Analysis

What AIDS teaches us

09/16/2022 Rony Brauman

In this article, Rony Brauman identifies the dynamics and events that made bending the HIV/AIDS epidemic curve possible. He explains the climate in which the tug-of-war with parts of the pharmaceutical industry played out from MSF’s perspective, and recalls that fears about international security and political stability also helped push governments to mobilise against the epidemic.

Read more
Video

Doing Drugs – Video briefing on access to medicines

02/03/2022

On 3rd and 4th February 2022, the CRASH organised a workshop aimed at the leaders, operational managers and members of MSF France, to shed light on the current debates on access to medicines, and to determine together which issues are the most relevant to resolve. In preparation for this workshop, the CRASH asked experts external to MSF to explain their vision of today’s pharmaceutical industry system, with subjects that ranged from pre-development to distribution, and included patents and quality-related issues.

Read more
Analysis

About the possibility of controlling an HIV epidemic hotspot

11/14/2021 Elba Rahmouni Pierre Mendiharat Léon Salumu Luzinga

This article was first released in the 18th volume of the Humanitarian Alternatives magazine. Designed to reduce the incidence of HIV/AIDS in a Kenyan district, a Médecins Sans Frontières project successfully exceeded the “90-90-90” target set by UNAIDS. A look back on the results that the authors of this article - Pierre Mendiharat, Deputy director of operations at MSF France and Léon Salumu Luzinga, Program manager at MSF France, interviewed by Elba Rahmouni - believe are encouraging but by no means a guarantee that the epidemic will be over by 2030.

Read more
Painting "Tuko Poa" benches in Kibera Bryan Jaybee Cahier

Representations of HIV and impact on care seeking among the men of Homa Bay, Kenya

06/09/2020 Xavier Plaisancie

This study, conducted among the men of Homa Bay in Nyanza Province, Kenya, assesses the representations of HIV and impact on care seeking. It reveals that simply setting up a testing or care campaign does not necessarily mean that the entire population will participate; the message has to be tailored to the target population and fine-tuned even within that population.

Read more